A carregar...
Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both
The English High Court recently dismissed the Bayer pharmaceutical company’s challenge against a regional clinical commissioning group’s policy allowing NHS Trusts to use a cheaper, but unlicensed, alternative to a sight preserving eye treatment. This makes sober reading for companies marketing “on-...
Na minha lista:
| Publicado no: | Eye (Lond) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6461787/ https://ncbi.nlm.nih.gov/pubmed/30498264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-018-0280-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|